75 related articles for article (PubMed ID: 24832201)
1. Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution.
Koo DH; Ryu MH; Ryoo BY; Seo J; Lee MY; Chang HM; Lee JL; Lee SS; Kim TW; Kang YK
Gastric Cancer; 2015 Apr; 18(2):346-53. PubMed ID: 24832201
[TBL] [Abstract][Full Text] [Related]
2. Dynamic change in the peritoneal cancer index based on CT after chemotherapy in the overall survival prediction of gastric cancer patients with peritoneal metastasis.
Wei YY; Cai JY; Wang LL; Yang J; Li YL; Li XT; Zhang XT; Shi YJ; Tang L
J Cancer Res Clin Oncol; 2024 Apr; 150(5):222. PubMed ID: 38687350
[TBL] [Abstract][Full Text] [Related]
3. The full management from first-line to third-line treatments in patients with Her-2-negative advanced gastric cancer.
Chang C; Pei Y; Xu J; Zhang W; Zhang J; Shi S
Front Oncol; 2022; 12():949941. PubMed ID: 36457494
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and Prognostic Factors of Metastatic Gastric Cancer: A Single-Center Experience.
Aseafan M; Gad AM; Alshamsan B; Agha N; Alhanash A; Aljubran AH; Alzahrani A; Bazarbashi S
Cureus; 2022 Aug; 14(8):e28426. PubMed ID: 36043200
[TBL] [Abstract][Full Text] [Related]
5. New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy.
Koo DH; Ryu MH; Lee MY; Moon MS; Kang YK
World J Gastroenterol; 2021 Dec; 27(48):8357-8369. PubMed ID: 35068874
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab.
Cho H; Ryu MH; Lee HE; Kim HD; Kang YK
Cancer Immunol Immunother; 2022 Apr; 71(4):829-838. PubMed ID: 34420059
[TBL] [Abstract][Full Text] [Related]
7. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort.
Koemans WJ; Lurvink RJ; Grootscholten C; Verhoeven RHA; de Hingh IH; van Sandick JW
Gastric Cancer; 2021 Jul; 24(4):800-809. PubMed ID: 33495964
[TBL] [Abstract][Full Text] [Related]
8. Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2-Targeted Agent in the Real-World Setting.
Koo DH; Ryu MH; Lee MY; Chae H; Kim EJ; Moon MS; Kang YK
Cancer Res Treat; 2021 Apr; 53(2):436-444. PubMed ID: 33070558
[TBL] [Abstract][Full Text] [Related]
9. Recent Developments of Systemic Chemotherapy for Gastric Cancer.
Arai H; Nakajima TE
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32354119
[TBL] [Abstract][Full Text] [Related]
10. Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review.
Chan WL; Lam KO; So TH; Lee VH; Kwong LD
Ther Adv Med Oncol; 2019; 11():1758835919859990. PubMed ID: 31285759
[TBL] [Abstract][Full Text] [Related]
11. The role of surgical resection before palliative chemotherapy in advanced gastric cancer.
Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Son SY; Hur H; Han SU; Sheen SS
Sci Rep; 2019 Mar; 9(1):4136. PubMed ID: 30858457
[TBL] [Abstract][Full Text] [Related]
12. The role of third-line chemotherapy in recurrent or metastatic gastric cancer: A cohort study with propensity score matching analysis.
Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Sheen SS
Medicine (Baltimore); 2018 Sep; 97(39):e12588. PubMed ID: 30278571
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns Among Patients with Metastatic and/or Unresectable Gastric Cancer in Brazil.
de Alencar Camara Vieira FM; de Souza Victorino APO; de Iracema Gomes Cubero D; Beato CAM; Minowa E; Julian GS; Novick D
J Gastrointest Cancer; 2019 Dec; 50(4):780-793. PubMed ID: 30078125
[TBL] [Abstract][Full Text] [Related]
14. C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer.
Wu S; He H; Liu H; Cao Y; Li R; Zhang H; Li H; Shen Z; Qin J; Xu J
Oncoimmunology; 2018; 7(6):e1433517. PubMed ID: 29872564
[TBL] [Abstract][Full Text] [Related]
15. Different long-term oncologic outcomes after radical surgical resection for neuroendocrine carcinoma and adenocarcinoma of the stomach.
Xie JW; Lu J; Lin JX; Zheng CH; Li P; Wang JB; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
Oncotarget; 2017 Aug; 8(34):57495-57504. PubMed ID: 28915689
[TBL] [Abstract][Full Text] [Related]
16. Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis.
Zheng Y; Zhu XQ; Ren XG
Medicine (Baltimore); 2017 Jun; 96(24):e6884. PubMed ID: 28614219
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.
Kim JH; Park SR; Ryu MH; Ryoo BY; Kim KP; Kim BS; Yoo MW; Yook JH; Kim BS; Kim J; Byeon SJ; Kang YK
Cancer Res Treat; 2018 Apr; 50(2):518-529. PubMed ID: 28546521
[TBL] [Abstract][Full Text] [Related]
18. A Prognostic Model Using Inflammation- and Nutrition-Based Scores in Patients With Metastatic Gastric Adenocarcinoma Treated With Chemotherapy.
Hsieh MC; Wang SH; Chuah SK; Lin YH; Lan J; Rau KM
Medicine (Baltimore); 2016 Apr; 95(17):e3504. PubMed ID: 27124056
[TBL] [Abstract][Full Text] [Related]
19. Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer.
Lee KW; Lee JH; Kim JW; Kim JW; Ahn S; Kim JH
J Cancer Res Clin Oncol; 2016 Mar; 142(3):687-97. PubMed ID: 26567125
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
